Quarterly report pursuant to Section 13 or 15(d)

Nature of Operations and Summary of Significant Accounting and Reporting Policies (Details Narrative)

v3.8.0.1
Nature of Operations and Summary of Significant Accounting and Reporting Policies (Details Narrative) - USD ($)
 3 Months Ended
Apr. 20, 2017
Sep. 30, 2017
Sep. 30, 2016
Jun. 30, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Common stock, shares authorized 100,000,000 100,000,000   100,000,000
Common stock, par value $ 0.001 $ 0.001   $ 0.001
Preferred stock, shares authorized 1,500,005 1,500,005    
Reverse stock split one-for-two hundred and fifty (1:250)      
Cash equivalents    
Value added tax receivable   7,142   $ 8,111
Research and development expense   $ 563,739 $ 161,197  
Employee Stock Option [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Antidilutive securities excluded from computation of earnings per share, amount   572,000    
Warrant [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Antidilutive securities excluded from computation of earnings per share, amount   149,517    
Common Stock [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Antidilutive securities excluded from computation of earnings per share, amount   21,962,241